In anticipation of the ESMO 2024 Congress, Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, previews various clinical trials and studies to be presented, including those on immunotherapy for metastatic kidney cancer, HIF inhibition, treatments for non-clear cell kidney cancer, and novel biomarkers for predicting treatment responses. — ...